Suchergebnisse - "Xia, Zhongjun"

PubPharm (76)

11

Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming

enthalten in: Molecular cancer | 2022

von Liang, Y. | He, H. | Wang, W. | +7

12

Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming

enthalten in: Molecular cancer | 2022

von Liang, Y. | He, H. | Wang, W. | +7

13

Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming

enthalten in: Molecular cancer | 2022

von Liang, Y. | He, H. | Wang, W. | +7

14

Traditional Chinese medicine preparation for promoting early healing of fracture and preparation method of traditional Chinese medicine preparation

enthalten in: Europäisches Patentamt | 2022

von ZHAO DEWEI | XIA ZHONGJUN | WANG TIENAN | +2

15

Traditional Chinese medicine oral preparation for promoting early healing of fracture and repairing traumatic injury and preparation method of traditional Chinese medicine oral preparation

enthalten in: Europäisches Patentamt | 2022

von ZHAO DEWEI | XIA ZHONGJUN | WANG TIENAN | +2

16

Traditional Chinese medicine preparation for treating bone trauma blood stasis swelling and pain and preparation method thereof

enthalten in: Europäisches Patentamt | 2022

von ZHAO DEWEI | XIA ZHONGJUN | XUE DONGLING | +4

17

Efficacy and safety comparison between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma

enthalten in: Annals of hematology | 2022

von Guan, J. | Sun, F. | Wang, J. | +11

18

Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH) : a phase II, single-arm study

enthalten in: BMC medicine | 2022

von Qiu, L. | Xia, Z. | Fu, C. | +20

19

Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study

enthalten in: BMC medicine | 2022

von Qiu, L. | Xia, Z. | Fu, C. | +20

20

Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study

enthalten in: BMC medicine | 2022

von Qiu, L. | Xia, Z. | Fu, C. | +20